Back

The anti-cancer tyrosine kinase inhibitor sorafenib reduces cardiac contractile force by reducing cardiomyocyte calcium transient amplitude.

29 August 2017 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 6 - Chronic heart failure (CHF) Cardiotoxicity of drugs ESC Premium Access ESC Congress 2017

About the speaker

Photo
Mr Christopher Schneider

Graz (Austria)

28 More presentations in this session

Presentation thumbnail
Doctor A. Cho (Vienna, AT)
Abstract
Presentation thumbnail
Associate Professor S. Joho (Toyama, JP)
Abstract
Presentation thumbnail
Mr E. Sole Gonzalez (Barcelona, ES)
Abstract Slides
Presentation thumbnail
Doctor L. Cheng (Shanghai, CN)
Abstract
Presentation thumbnail
Associate Professor A. Martin Garcia (Salamanca, ES)
Abstract Slides

Access the full session

Session thumbnail
Poster session 6 - Chronic heart failure (CHF)

The Event

Event poster

ESC Congress 2017

29 August 2017 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources